arrow
E

Elena Garralda

hospital universitari vall d'hebron
H指数:46
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial

双特异性双T细胞激动剂invikafusp alfa在实体瘤中的研究:第1/2期START-001试验

2026-10-230
PRE
Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma

I期/ Ib期研究评估NIZ985单药治疗及联合抗PD-1药物在晚期实体瘤或淋巴瘤患者中的安全性、有效性、药代动力学和药效动力学

2026-06-240
PRE
Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity

六聚体抗体HexaBody-DR5/DR5在恶性实体瘤中的安全性与有效性:I/IIa期试验结果及对观察到肝毒性的转化医学见解

2026-05-220
OAAI
MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors

MDX-2001-101研究方案:一项评估MDX2001单药治疗在晚期实体瘤患者中的I/IIa期、多中心、首次人体、开放标签临床试验

2026-01-010
OA
Clinically feasible liver tumour cell size measurement through histology-informed in vivo diffusion MRI

通过基于组织学信息的在体扩散MRI进行临床可行的肝脏肿瘤细胞尺寸测量

2025-11-200
OAAI
Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors

基因组可操作性及匹配的靶向疗法在为期十年的机构实体瘤精准医学项目中的应用

2025-11-060
OAAI
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial

PD1疗法在PD1高表达mRNA肿瘤中的疗效:SOLTI-1904 ACROPOLI II期试验中队列1和队列2的结果

2025-09-300
OAAI
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis

使用肿瘤浸润淋巴细胞联合高剂量重组白细胞介素2进行过继治疗在晚期皮肤黑色素瘤中的安全性:一项系统评价和Meta分析

2025-04-080
PRE
A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer

一种基于CT的、由深度学习驱动的自动肝脏肿瘤检测与勾画工具,用于癌症患者

2025-04-010
OAAI
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours ( vol 637 , pg 1218 , 2025)

中和GDF-15可以克服实体瘤中的抗PD-1和抗PD-L1耐药性(vol 637,pg 1218,2025)

NATURE
IF48.5
2025-02-250
OA
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

中和GDF-15可以克服实体瘤中抗PD-1和抗PD-L1的耐药性

Nature
IF48.5
2024-12-110
OAAI
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

ESMO肿瘤不可知分类器和筛选器 (etac-s): 一种评估分子引导疗法的肿瘤不可知潜力和指导药物开发的工具

2024-11-012
OAAI